Merrie Mosedale, Ph.D.
UNC Eshelman School of Pharmacy, 3309 Kerr Hall, CB# 7569, Chapel Hill, NC, 27599-7569
Merrie Mosedale, Ph.D., is an assistant professor in the Division of Pharmacotherapy and Experimental Therapeutics. Mosedale is also the assistant director of the Institute for Drug Safety Sciences where she leads the Translational Pharmacogenomics Research Program. Through partnerships with pharmaceutical companies and academic scientists, Mosedale is working to solve safety problems by integrating cutting-edge pharmacogenomics approaches with novel in vivo, in vitro, and in silico platforms. Her goal is to develop pioneering new technologies that will impact regulatory decisions and policies.
Currently, Mosedale is focusing on the application of 1) mouse genetics to identify individual susceptibilities to adverse drug reactions in humans, 2) organotypic culture models to understand mechanisms of drug toxicities, and 3) exosome biology to predict toxicity liabilities earlier in drug development. Findings from her research highlight the potential for these novel approaches to improve human risk assessment in drug-safety testing as well as to provide mechanistic insights into drug toxicity. She has been recognized for her work by the Society of Toxicology and the American Society for Pharmacology and Experimental Therapeutics.
Prior to joining UNC, Mosedale was a research investigator at the Hamner Institutes for Health Sciences. She received her B.S. from Duke University and her Ph.D. from the University of California, San Diego.Publications